NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.070
-0.020 (-1.83%)
Jan 14, 2026, 4:00 PM EST - Market closed
NeuroSense Therapeutics Market Cap
NeuroSense Therapeutics has a market cap or net worth of $31.78 million as of January 15, 2026. Its market cap has increased by 7.35% in one year.
Market Cap
31.78M
Enterprise Value
31.11M
1-Year Change
7.35%
Ranking
Category
Stock Price
$1.07
Market Cap Chart
Since the IPO on December 9, 2021, NeuroSense Therapeutics's market cap has decreased from $64.61M to $31.78M, a decrease of -50.82%. That is a compound annual growth rate of -15.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 14, 2026 | 31.78M | 39.14% |
| Dec 31, 2025 | 22.84M | -17.70% |
| Dec 31, 2024 | 27.75M | 158.68% |
| Dec 29, 2023 | 10.73M | -24.68% |
| Dec 30, 2022 | 14.24M | -46.24% |
| Dec 31, 2021 | 26.49M | -59.00% |
| Dec 9, 2021 | 64.61M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 967.91B |
| Johnson & Johnson | 505.28B |
| AbbVie | 388.90B |
| UnitedHealth Group | 308.45B |
| AstraZeneca | 295.57B |
| Novartis AG | 274.30B |
| Merck & Co. | 271.01B |
| Novo Nordisk | 263.26B |